Release form, composition:
Solution for intraocular injection. 1 ml contains:
Methylethylpiridinol hydrochloride (emoxipin) 10 mg.
As a vasoprotector, reduces vascular permeability, is an inhibitor of free radical processes, antioxidant and antihypoxant.
Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (camp and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduce vascular permeability and the risk of hemorrhage, contributes to their resolution. Expands coronary vessels, in acute period of myocardial infarction limits the amount of necrosis, improves heart contractility and function of the conduction system. With high blood pressure hypotensive effect. Acute ischemic disorders of cerebral circulation reduces the severity of neurological symptoms, increases the resistance of tissue to hypoxia and ischemia.
Has retinoprotective properties, protects the retina from damaging action of light of high intensity, promotes the resorption of intraocular hemorrhages, improves microcirculation of the eye.
In the complex therapy: consequences of violations of cerebral circulation ischemic and hemorrhagic nature of brain injury, postoperative EPI – and subdural hematomas, acute myocardial infarction, prevention of reperfusion syndrome, unstable angina.
Subconjunctival and intraocular hemorrhage, angioretinopathia (including diabetic), chorioretinal degeneration (including atherosclerotic origin), dystrophic keratitis, vascular thrombosis retinal complications of myopia, protection of the cornea (if wearing contact lenses) and the retina from exposure to high intensity light (laser and sunburn, laser coagulation with), trauma, inflammation and burns to the cornea, cataracts (i.e. prevention in individuals older than 40 years), surgery on the eyes, as after the operation for glaucoma with detachment of the choroid.
In neurology and cardiology – in/in the drip (20-40 drops/min), 20-30 ml of 3% solution (600-900 mg) 1-3 times a day for 5-15 days (after the drug is diluted in 200 ml of 0.9% NaCl solution or 5% dextrose solution). The duration of treatment depends on the disease. In the subsequent transition to the/m introduction – 3-5 ml of 3% solution 2-3 times a day for 10-30 days.
In ophthalmology – or subconjunctival parabulbarno, 1 time a day or every other day. Subconjunctival for 0.2-0.5 ml of 1% solution (2-5 mg), parabulbarno – 0.5-1 ml of 1% solution (5-1 mg). The duration of treatment is 10 to 30 days may repeat the course 2-3 times a year.
If necessary retrobulbar in 0.5-1 ml of 1% solution of 1 times a day for 10-15 days.
To protect retinal laser coagulation (i.e., the limiting and destructive coagulation of tumors) – parabulbarno or retrobulbar in 0.5-1 ml of 1% solution for 24 hours and for 1 hour until coagulation then at the same doses (0.5 ml of 1% solution) 1 times a day for 2-10 days.
Short-term excitation, drowsiness, increased blood pressure, allergic reactions (skin rashes, etc.), local reactions – pain, burning, itching, redness, induration periorbital tissues (dissolves itself).
Application of pregnancy and breastfeeding
Contraindicated in pregnancy.
Treatment should be under the control of blood pressure and blood clotting.
Pharmaceutically incompatible with other drugs.
|The purpose of the medication||Anti-aggregants|